Renaissance Technologies LLC Acquires 83,800 Shares of Hookipa Pharma Inc (NASDAQ:HOOK)

Renaissance Technologies LLC lifted its holdings in Hookipa Pharma Inc (NASDAQ:HOOK) by 38.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 302,246 shares of the company’s stock after buying an additional 83,800 shares during the quarter. Renaissance Technologies LLC’s holdings in Hookipa Pharma were worth $179,000 at the end of the most recent quarter.

Separately, Acadian Asset Management LLC boosted its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the last quarter. Hedge funds and other institutional investors own 63.88% of the company’s stock.

Wall Street Analyst Weigh In

Separately, JMP Securities lifted their price objective on Hookipa Pharma from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th.

Hookipa Pharma Trading Down 4.6 %

Shares of HOOK opened at $3.71 on Monday. The firm has a fifty day simple moving average of $4.73 and a 200 day simple moving average of $6.44. The stock has a market capitalization of $36.71 million, a price-to-earnings ratio of -0.74 and a beta of 0.83. Hookipa Pharma Inc has a 12 month low of $3.62 and a 12 month high of $11.30.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.44) by ($0.08). The company had revenue of $1.29 million during the quarter, compared to analyst estimates of $5.68 million. Hookipa Pharma had a negative net margin of 93.16% and a negative return on equity of 36.81%.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.